COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition

Abstract

PDE4 inhibition reduces sputum eosinophils in those COPD patients with higher eosinophil counts. This evidence supports an effect of PDE4 inhibitors on eosinophilic inflammation. https://bit.ly/3airXw7

Trial registration: ClinicalTrials.gov NCT03004417.

Conflict of interest statement

Conflict of interest: D. Singh reports received personal fees from Chiesi during the conduct of this study; outside the submitted work, he reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance, and Verona, and personal fees from Cipla, Genentech and Peptinnovate. Conflict of interest: H. Watz reports personal fees from Chiesi during the conduct of the study; outside the submitted work, he reports personal fees from Bayer, GSK, Boehringer Ingelheim, Novartis, AstraZeneca, BerlinChemie and Roche. Conflict of interest: K.M. Beeh declares that no personal payments were received from any pharmaceutical entity in the past 5 years; and is a full time employee of insaf Respiratory Research Institute, which has received compensation for services on advisory boards or consulting for Ablynx, Almirall, AstraZeneca, Berlin Chemie, Boehringer, Chiesi, Cytos, Mundipharma, Novartis, Pohl Boskamp and Zentiva; the institution has received compensation for speaker activities in scientific meetings supported by Almirall, AstraZeneca, Berlin Chemie, Boehringer, Cytos, ERT, GSK, Novartis, Pfizer, Pohl Boskamp and Takeda; the institution has further received compensation for design and performance of clinical trials from Almirall, Altana/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, MSD, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Revotar, Teva, Sterna and Zentiva. Conflict of interest: O. Kornmann received fees paid to his institution from Chiesi for conducting this study; and reports personal fees as speaker or advisory board member from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi and Novartis. Conflict of interest: B. Leaker has nothing to disclose. Conflict of interest: B. Colgan has nothing to disclose. Conflict of interest: G. Lucci is an employee of Chiesi, the sponsor of the trial. Conflict of interest: A. Emirova is an employee of Chiesi, the sponsor of the trial. Conflict of interest: M.A. Nandeuil is an employee of Chiesi, the sponsor of the trial. Conflict of interest: D. Santoro is an employee of Chiesi, the sponsor of the trial. Conflict of interest: D. Balzano is an employee of Chiesi, the sponsor of the trial. Conflict of interest: M. Govoni is an employee of Chiesi, the sponsor of the trial.

Figures

FIGURE 1

a) Effect of CHF6001 (800 ug and 1600 ug twice daily) over placebo on sputum eosinophil per cent levels in eosinophilhigh and eosinophillow patients. b) Correlation between blood absolute and percentage sputum eosinophil values with regression line and 95% confidence intervals. Receiver operating characteristic (ROC) area under the curve (AUC) analysis of sensitivity and specificity of c) per cent and d) absolute blood eosinophil count to predict eosinophilhigh and eosinophillow patients, with the corresponding 95% confidence intervals.